Stimulating pharmaceutical innovation in the EU

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 3, 2011, Pages 235-239

  Annemans, Lieven ^a   Cleemput, Irina ^b   Hulstaert, Frank ^b   Simoens, Steven ^c  

^a GHENT UNIVERSITY   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

clinical trials; intellectual property rights; medical needs; orphan medicines; pharmaceutical innovation

Indexed keywords

DRUG INDUSTRY; DRUG MARKETING; EUROPEAN UNION; FINANCIAL MANAGEMENT; HEALTH CARE NEED; HEALTH CARE POLICY; HEALTH CARE SYSTEM; LAW; MEDICAL RESEARCH; PATENT; PHARMACEUTICAL CARE; QUALITY CONTROL; RESEARCH PRIORITY; REVIEW; SYMPOSIUM; WORKSHOP;

CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; EUROPEAN UNION; HUMANS;

EID: 79959236542     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.19     Document Type: Review

References (5)

1. Grootendorst P, Pierard E, Shim M. Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Rev. Pharmacoeconomics Outcomes Res. 9(4), 353-364 (2009)
2. Annemans L, Arickx F, Belle O et al. A call to make valuable innovative medicines available in the European Union. Background report for the ministerial conference 'Innovation and solidarity on pharmaceuticals'. RIZIV, Brussels, Belgium (2010)
3. Docteur E, Paris V. Improving health system efficiency: achieving better value for money. Presented at: Joint European Commission/OECD Conference. Brussels, Belgium, 17 September 2008.
4. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. A mounting dilemma: balancing early market access to new drugs against the need for comprehensive data on benefits and risks. Nature Rev. Drug Discov. 7, 818-826 (2008)
5. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets. Health Pol. 97(2-3), 173-179 (2010).